克唑替尼治疗间变性淋巴瘤激酶重排晚期非小细胞肺癌疗效观察
摘要
<正>2016年发布的中国癌症统计数据显示,在我国肺癌是发病率、死亡率最高的癌症[1]。其中非小细胞肺癌(NSCLC)约占肺癌的80%~85%[2]。传统的晚期NSCLC的治疗以化疗为主,但疗效有限,患者的中位生存时间约10个月。靶向治疗的问世使部分患者的生存期大大提高,同时明显改善了患者的生活质量。2007年,发现了棘皮动物微管相关蛋白4与间变性淋巴瘤激酶(echinoderm microtubule asso-
引文
[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2]Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.
[3]Travis WD,Brambilla E,Nicholson AG,et al.The 2015 World Health Organization classification of lung tumors:impact of genetic,clinical and radiologic advances since the 2004 classification[J].J Thorac Oncol,2015,10(9):1243-1260.
[4]Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561-566.
[5]Kazandjian D,Blumenthal GM,Chen HY,et al.FDA approval summary:crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements[J].Oncologist,2014,19(10):e5-11.
[6]高峨嵋,赵军,卓明磊,等.克唑替尼治疗晚期NSCLC患者单中心回顾性分析[J].中国肺癌杂志,2016,19(3):161-168.
[7]Shaw AT,Yeap BY,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK[J].J Clin Oncol,2009,27(26):4247-4253.
[8]Kwak EL,Bang YJ,Camidge DR,et al.Anaplastic lymphoma kinase inhibition in nonvsmall-cell lung cancer[J].N Engl J Med,2010,363(18):1693-1703.
[9]Camidge DR,Bang YJ,Kwak EL,et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer:updated results from a phase 1 study[J].Lancet Oncol,2012,13(10):1011-1019.
[10]Shaw AT,Kim DW,Nakagawa K,et al.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J].N Engl J Med,2013,368(25):2385-2394.
[11]郑剑滔,郑斌,郭朝晖,等.非小细胞肺癌患者EML4-ALK基因表达与临床特征及近期生存的关系[J].福建医科大学学报,2016,50(1):20-24.
[12]张红,王志强.克唑替尼治疗间变性淋巴瘤激酶融合基因阳性晚期非小细胞肺癌疗效观察[J].中国冶金工业医学杂志,2016,33(5):497-498.
[2]Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.
[3]Travis WD,Brambilla E,Nicholson AG,et al.The 2015 World Health Organization classification of lung tumors:impact of genetic,clinical and radiologic advances since the 2004 classification[J].J Thorac Oncol,2015,10(9):1243-1260.
[4]Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561-566.
[5]Kazandjian D,Blumenthal GM,Chen HY,et al.FDA approval summary:crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements[J].Oncologist,2014,19(10):e5-11.
[6]高峨嵋,赵军,卓明磊,等.克唑替尼治疗晚期NSCLC患者单中心回顾性分析[J].中国肺癌杂志,2016,19(3):161-168.
[7]Shaw AT,Yeap BY,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK[J].J Clin Oncol,2009,27(26):4247-4253.
[8]Kwak EL,Bang YJ,Camidge DR,et al.Anaplastic lymphoma kinase inhibition in nonvsmall-cell lung cancer[J].N Engl J Med,2010,363(18):1693-1703.
[9]Camidge DR,Bang YJ,Kwak EL,et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer:updated results from a phase 1 study[J].Lancet Oncol,2012,13(10):1011-1019.
[10]Shaw AT,Kim DW,Nakagawa K,et al.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J].N Engl J Med,2013,368(25):2385-2394.
[11]郑剑滔,郑斌,郭朝晖,等.非小细胞肺癌患者EML4-ALK基因表达与临床特征及近期生存的关系[J].福建医科大学学报,2016,50(1):20-24.
[12]张红,王志强.克唑替尼治疗间变性淋巴瘤激酶融合基因阳性晚期非小细胞肺癌疗效观察[J].中国冶金工业医学杂志,2016,33(5):497-498.